Skip to main content

Regulatory and Washington

  • Coalition for Pulmonary Fibrosis, CDC partner to promote flu shots

    CULVER CITY, Calif. — An advocacy group focused on a rare lung disorder is working with government authorities to educate patients about the need to get flu shots.

    The Coalition for Pulmonary Fibrosis said it would partner with the Centers for Disease Control and Prevention to inform patients about the need for immunizations. PF is a disorder with no known cause or cure that causes scarring and deterioration of the lungs, affecting about 128,000 Americans.

  • Healthy holiday shopping season, but trouble could lie ahead, NRF says

    NEW YORK — Despite caution among consumers, retailers wrapped up 2012 with a healthy holiday shopping season, according to a new report by a retailing trade group.

    The National Retail Federation said Tuesday that holiday retail sales increased 3% over the year before, to $579.8 billion. December retail sales increased 0.8% seasonally adjusted from November and 2.1% unadjusted year over year. Nevertheless, the 3% increase was still below the NRF's projected 4.1% growth. Meanwhile, nonstore holiday sales grew 11.1%.

  • ‘Pay for delay’ deals will face review by SCOTUS

    The nation’s highest court has agreed to hear three cases stemming from the longstanding but controversial practice by which branded and generic drug makers agree to delay introduction of a me-too medicine as its brand-name counterpart nears the end of its patent protection. A ruling by the Supreme Court could alter the delicate balance sometimes struck between the two industries as they scramble to either delay or hasten the onset of generic competition for big-selling, patented drugs.

  • GPhA appoints Claire Sheahan as VP communications

    WASHINGTON — The Generic Pharmaceutical Association has appointed a new officer to head its communications, the industry trade group said Tuesday.

    The GPhA announced the appointment of Claire Sheahan as VP communications, effective Jan. 22. Sheahan previously worked as SVP and partner of communications firm Fleishman-Hillard, leading the firm's Washington-based healthcare practice.

  • Reports: Otsuka can block Apotex's generic version of Abilify

    NEW YORK — Drug maker Otsuka Pharmaceuticals can keep generic versions of its schizophrenia drug off the market, according to published reports.

    Bloomberg reported that the Supreme Court upheld a ruling that allowed Otsuka to block Canadian generic drug maker Apotex from marketing a version of the antipsychotic Abilify (aripiprazole), which Otsuka co-markets with Bristol-Myers Squibb.

  • Reports: Alabama man can sue branded drug makers over generic drug side effects

    NEW YORK — The state supreme court in Alabama ruled that brand-name drug companies could be sued if patients suffer complications from generic versions of their medicines, according to published reports.

    According to The New York Times, an Alabama man named Danny Weeks claimed he developed tardive dyskinesia after taking generic versions of Pfizer's acid reflux drug Reglan (metoclopramide). Pfizer acquired rights to the drug when it bought Wyeth in 2009, and generic drug makers Teva and Actavis, now owned by Watson, make generic versions.

  • Six for 2013

    Rather than take off for the holidays, the editors of Drug Store News took a look at the year ahead and the trends, issues and headlines that will makes the news in 2013.

    What do you think? Follow us on Twitter and LinkedIn, and join the discussion there, or post your comments on DrugStoreNews.com ... Or, you can pretend it’s still 1999 and email your comments to [email protected]. Just don’t fax us.

  • Enough flu vaccines to go around - just not everywhere at once

    Amid an unusually strong flu season that the Centers for Disease Control and Prevention has called an epidemic, supplies of flu vaccines are running low, and some people hoping to get immunized are having trouble finding them.

X
This ad will auto-close in 10 seconds